Markets:

Overview

News

Currencies

International

Treasuries

Mirati Therapeutics, Inc. - Common Stock (NQ:MRTX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 22, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirati Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations

December 10, 2021

FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel...

Via FinancialNewsMedia

Topics Artificial Intelligence

Investigation Announced for Long-Term Investors in Mirati Therapeutics, Inc. (NASDAQ:MRTX) ↗

December 07, 2021

San Diego, CA -- (SBWIRE) -- 12/07/2021 -- Certain directors of Mirati Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.

Via SBWire

Topics Regulatory Compliance

Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer

November 22, 2021

From Verastem Oncology

Via Business Wire

Expert Ratings For Mirati Therapeutics ↗

November 19, 2021

Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst rating...

Via Benzinga

Expert Ratings For Mirati Therapeutics ↗

September 21, 2021

Over the past 3 months, 5 analysts have published their opinion on Mirati Therapeutics (NASDAQ:

Via Benzinga

New CEO At Mirati Therapeutics ↗

September 20, 2021

Amid data readouts from adagrasib, sitravatinib programs, Mirati Therapeutics Inc (NASDAQ: MRTX) has appointed David Meek as Chief Executive Officer,...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗

November 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...

Via Benzinga

Mirati Posts More Responses For Adagrasib-Keytruda Combo In Lung Cancer Setting ↗

November 09, 2021

In its Q3 earnings release, Mirati Therapeutics Inc (NASDAQ: MRTX) posted preliminary results from the Phase 1b cohort of the KRYSTAL-1 study evaluating adagrasib...

Via Benzinga

NASDAQ:MRTX Investor Notice: Investigation over Possible Securities Laws Violations by Mirati Therapeutics, Inc. ↗

November 08, 2021

San Diego, CA -- (SBWIRE) -- 11/08/2021 -- Mirati Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

Topics Regulatory Compliance

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

Mid-Afternoon Market Update: loanDepot Surges After Q3 Results; Mirati Therapeutics Shares Slide ↗

November 01, 2021

Toward the end of trading Monday, the Dow traded up 0.12% to 35,863.70 while the NASDAQ rose 0.18% to 15,525.52. The S&P, however, fell 0.10% to 4,600.81. The U.S. has the...

Via Benzinga

Topics Stocks

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 01, 2021

Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's regular session. As of 12:30 EST, this security is trading at a volume...

Via Benzinga

Earnings Scheduled For November 8, 2021 ↗

November 08, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...

Via Benzinga

64 Biggest Movers From Yesterday ↗

November 02, 2021

Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares climbed 137.4% to close at $6.03 on Monday on abnormally-high volume. The stock is seeing increased interest by traders on...

Via Benzinga

Mid-Day Market Update: Dow Rises 50 Points; ANI Pharmaceuticals Shares Jump ↗

November 01, 2021

Midway through trading Monday, the Dow traded up 0.14% to 35,871.27 while the NASDAQ rose 0.23% to 15,534.49. The S&P also fell, dropping 0.03% to 4,603.98. The U.S. has the...

Via Benzinga

Topics Stocks

40 Stocks Moving In Monday's Mid-Day Session ↗

November 01, 2021

Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares jumped 250% to $8.91 on abnormally-high volume. The stock is seeing increased interest by traders on social media. Also, the...

Via Benzinga

Mirati Therapeutics COO, CMO Exit, Completing Management Overhaul ↗

November 01, 2021

Shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) are retreating sharply Monday following two executive departures. What Happened: Mirati, a clinical-stage targeted oncology...

Via Benzinga

Here's My Top Value Stock To Buy Right Now ↗

November 01, 2021

EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications.

Via Talk Markets

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT ↗

October 06, 2021

Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal...

Via Benzinga

What 6 Analyst Ratings Have To Say About Mirati Therapeutics ↗

September 23, 2021

Over the past 3 months, 6 analysts have published their opinion on Mirati Therapeutics (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 ↗

September 23, 2021

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:

Via Benzinga

9 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗

September 21, 2021

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

September 21, 2021

RBC Capital boosted MSCI Inc. (NYSE:MSCI) price tar...

Via Benzinga

Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer ↗

September 20, 2021

Mirati Therapeutics easily beat Amgen's test results in colon cancer.

Via Investor's Business Daily

Why Mirati Therapeutics Stock Is Trading Higher Today ↗

September 20, 2021

Mirati Therapeutics Inc (NASDAQ: MRTX) is trading higher Monday after the company announced clinical data with investigational adagrasib as monotherapy and in combination...

Via Benzinga

35 Stocks Moving In Monday's Mid-Day Session ↗

September 20, 2021

Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. (NASDAQ: EDSA) jumped 30.6% to $7.68 after the company...

Via Benzinga

Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients ↗

September 20, 2021

Mirati Therapeutics Inc (NASDAQ: MRTX) has announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500 of sitravatinib combined...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.